Hereditary Angioedema Therapeutics Market Size, Share, Industry Trends and Forecast to 2033
This report provides an in-depth analysis of the Hereditary Angioedema Therapeutics market, focusing on market size, trends, and forecasts from 2023 to 2033. Insights into regional dynamics, competitive landscape, and key industry players are also included.
| Metric | Value |
|---|---|
| Study Period | 2023 - 2033 |
| 2023 Market Size | $5.60 Billion |
| CAGR (2023-2033) | 6.8% |
| 2033 Market Size | $11.01 Billion |
| Top Companies | Takeda Pharmaceuticals, CSL Behring, Shire (part of Takeda) |
| Last Modified Date | 15 Nov 2024 |
Hereditary Angioedema Therapeutics Market Report (2023 - 2033)
Hereditary Angioedema Therapeutics Market Overview
What is the Market Size & CAGR of Hereditary Angioedema Therapeutics market in 2023?
Hereditary Angioedema Therapeutics Industry Analysis
Hereditary Angioedema Therapeutics Market Segmentation and Scope
Request a custom research report for industry.
Hereditary Angioedema Therapeutics Market Analysis Report by Region
Europe Hereditary Angioedema Therapeutics Market Report:
In Europe, the HAE market is valued at USD 1.49 billion in 2023, projected to grow to USD 2.93 billion by 2033. The region benefits from high healthcare expenditure and a well-established regulatory framework for new therapies.Asia Pacific Hereditary Angioedema Therapeutics Market Report:
In the Asia Pacific region, the market is valued at USD 1.12 billion in 2023, expected to reach USD 2.21 billion by 2033. Rapid urbanization and improved healthcare infrastructure contribute to market growth in developing countries.North America Hereditary Angioedema Therapeutics Market Report:
North America leads the market, with a value of USD 2.13 billion in 2023, expecting to grow to USD 4.18 billion by 2033. The presence of numerous key players and advanced healthcare systems drive robust growth.South America Hereditary Angioedema Therapeutics Market Report:
The South American market for HAE therapeutics is valued at USD 0.28 billion in 2023 and projected to reach USD 0.55 billion by 2033. Increased awareness and healthcare access are pivotal to its expansion.Middle East & Africa Hereditary Angioedema Therapeutics Market Report:
The Middle East and Africa market stands at USD 0.58 billion in 2023, with expectations to reach USD 1.14 billion by 2033. Increased healthcare investments and awareness programs are significant contributors to market growth.Request a custom research report for industry.
Hereditary Angioedema Therapeutics Market Analysis By Therapy Type
Global Hereditary Angioedema Therapeutics Market, By Therapy Type Market Analysis (2023 - 2033)
In the therapeutics market for hereditary angioedema, C1 inhibitors dominate with a market size of USD 3.82 billion in 2023, projected to increase to USD 7.51 billion by 2033, holding a 68.19% market share. Bradykinin receptor antagonists account for USD 1.49 billion in 2023, expected to grow to USD 2.92 billion by 2033, capturing 26.57% of the market. Other therapies, including Acquired Angioedema treatments, show minor but growing contributions.
Hereditary Angioedema Therapeutics Market Analysis By Route Of Administration
Global Hereditary Angioedema Therapeutics Market, By Route of Administration Market Analysis (2023 - 2033)
Subcutaneous injections currently dominate the market with a size of USD 3.82 billion in 2023, predicted to rise to USD 7.51 billion by 2033, constituting 68.19% of the administration methods. Intravenous injections follow, valued at USD 1.49 billion in 2023 and estimated to reach USD 2.92 billion by 2033, holding a 26.57% share. Oral administration remains a smaller segment, with a size of USD 0.29 billion in 2023, likely to increase to USD 0.58 billion by 2033.
Hereditary Angioedema Therapeutics Market Analysis By Indication
Global Hereditary Angioedema Therapeutics Market, By Indication Market Analysis (2023 - 2033)
The market for Hereditary Angioedema is distinguished by type, with Hereditary Angioedema Type I at USD 3.82 billion in 2023 and expected to grow to USD 7.51 billion by 2033. Type II also shows potential, expected to grow from USD 1.49 billion to USD 2.92 billion over the same period. Acquired Angioedema, while smaller, is projected to rise from USD 0.29 billion in 2023 to USD 0.58 billion by 2033.
Hereditary Angioedema Therapeutics Market Analysis By End User
Global Hereditary Angioedema Therapeutics Market, By End User Market Analysis (2023 - 2033)
Hospitals are the primary end-users in this market, accounting for USD 3.82 billion in 2023 and likely to reach USD 7.51 billion by 2033, maintaining a 68.19% market share. Clinics represent another significant segment, with a size of USD 1.49 billion in 2023, projected to reach USD 2.92 billion by 2033, which corresponds to a 26.57% share. Home care settings also contribute, with values incrementing from USD 0.29 billion to USD 0.58 billion by 2033.
Hereditary Angioedema Therapeutics Market Trends and Future Forecast
Request a custom research report for industry.
Global Market Leaders and Top Companies in Hereditary Angioedema Therapeutics Industry
Takeda Pharmaceuticals:
A leader in WFH (Hereditary Angioedema) therapies, Takeda provides advanced C1 esterase inhibitors and is at the forefront of HAE treatment innovation.CSL Behring:
Known for its extensive product line for plasma-derived therapies and innovative treatments for rare genetic disorders, including various HAE therapeutic options.Shire (part of Takeda):
Shire was pivotal in developing therapies that focus on the unique needs of HAE patients and was acquired by Takeda to enhance its portfolio.We're grateful to work with incredible clients.
